StreetAlpha.app
Home › Stocks › SPRY

ARS Pharmaceuticals, Inc. (SPRY)

Healthcare
$3.65
▲ +1.67%
LAST CLOSE · NOV 17

ARS Pharma develops and sells neffy, a nasal spray form of epinephrine for emergency treatment of severe allergic reactions. It last closed at $3.65 on Nov 17, up 1.67% on the day. SPRY last reported earnings on Thu, Aug 13, 2026. The average 12-month price target from 2 analysts is $18.50 (+406.8% from the last close), with a high of $20.00 and a low of $17.00.

AI Auto Pilots
Is SPRY in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$122.1M
−14.5% vs a year ago
Net income
−$199.9M
−163.6% margin
EPS (diluted)
−$2.01
Free cash flow
−$183.1M
−149.9% margin
Valuation
Market cap
$366.9M
100.5M shares
P/E
–
No P/E while losing money
Price to sales
3.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$25.6M
At Sep 30
Debt
$121.8M
At Sep 30
Shareholder equity
−$12.0M
Shares outstanding
100.5M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $5.5M$5.5MFY2021FY2022: $1.3M$1.3MFY2022FY2023: $30K$30KFY2023FY2024: $89.1M$89.1MFY2024FY2025: $84.3M$84.3MFY2025

From SPRY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Aug 13
2026 · After the close (AMC)
Reported EPS
-$0.63
vs -$0.55 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±22.4%
Priced in before that report
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated SPRY in the past 90 days, not enough for a consensus
Average 12-month target
$18.50
▲ 406.8% upside

Based on 2 analysts who set a price target on SPRY in the past 90 days. The average target is $18.50, with a high of $20.00 and a low of $17.00, compared with the last close of $3.65.

Low $17.00Avg $18.50High $20.00
Blue marker: last close $3.65
Highest target$20.00
Average target$18.50
Lowest target$17.00
Latest rating changes
Cantor FitzgeraldTarget lowered
Nov 6Buy$30 → $20
Raymond JamesDowngrade
Nov 6Buy$17
Leerink PartnersMaintained
Jun 25Buy$24
Cantor FitzgeraldMaintained
May 28Buy$30
DateFirmActionRatingPrice target
Nov 6Cantor FitzgeraldTarget loweredBuy$30 → $20
Nov 6Raymond JamesDowngradeBuy$17
Jun 25Leerink PartnersMaintainedBuy$24
May 28Cantor FitzgeraldMaintainedBuy$30
Loading…

Technical Analysis

SPRY · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 91% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 49). The nearest support is the 20 day average at $3.55, and the nearest resistance the Pivot R1 at $3.78.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 9.3%/day
Key levels
$13.1552 week high+260.3%
$6.97200 day average+91.0%
$5.20100 day average+42.5%
$4.13Swing high (Nov 11)+13.2%
$4.0050 day average+9.6%
$3.78Pivot R1+3.6%
$3.65Pivot+0.0%
$3.65Last close
$3.5520 day average−2.7%
$3.52Pivot S1−3.6%
$2.4452 week low−33.2%
$2.44Swing low (Nov 6)−33.2%
Indicators
RSI (14)48.51Middle of its rangeNeutral
MACD-0.14Above its signal lineBullish
Stochastic75.2Middle of its rangeNeutral
ADX (14)21.7Weak trend
Williams %R-28.4Oversold below −80, overbought above −20Neutral
CCI (20)13.3Oversold below −100, overbought above 100Neutral
Rate of change+19.7%Change over 10 sessionsBullish
ATR (14)$0.34Typical daily range, 9.3% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for SPRY

What happened before

See how SPRY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SPRY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SPRY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SPRY in the last 90 days.

Loading…

See today’s whale options flow across the market →

SPRY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●89 buying vs 99 selling
  • ▼Held by funds -2.2 pts
  • ▼Funds holding -19
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding187206−9.2%
In funds' top 1004−100.0%
Held by funds88.0%90.2%−2.2 pts
New / increased28 / 6136 / 73−18.3%
Reduced / sold out56 / 4356 / 31+13.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SPRY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRY is in one of them and how their past SPRY trades turned out.

SPRY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SPRY in an article yet. Here's the latest on the wider market.

About ARS Pharmaceuticals

ARS Pharma is a biopharmaceutical company that develops and sells neffy, an epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis. The product is given through the nose without a needle, and it is sold under other trade names in Europe, the U.K. and China. Its customers include patients, caregivers, and the doctors who prescribe it, and partners help commercialize the product in several countries. The company is headquartered in San Diego, California.

Headquarters
San Diego, CA
Founded
2016